BLAINJECTIONINJECTABLE
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
MARGENZA (margetuximab-cmkb) by MacroGenics is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2020.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MARGENZA (margetuximab-cmkb) is a monoclonal antibody antagonist of the HER2/neu receptor approved in December 2020 for HER2-positive cancers. It binds to HER2 to block tumor cell growth and survival signaling. The drug represents an engineered approach to HER2 targeting with potential advantages in certain patient populations.
Peak
Drug is in peak commercial lifecycle with 30% competitive pressure; mid-sized team operating in mature HER2 market with biosimilar and generic competition.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MARGENZA offers exposure to competitive oncology commercialization in a mature, high-stakes HER2 market where differentiation hinges on clinical messaging, payer contracting, and managed care strategy. Career growth potential is moderate due to market saturation and biosimilar/generic pressure, but oncology experience on a peak-stage biologic is valuable credential-building.
Brand Manager
Worked on MARGENZA at MacroGenics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.